HbA 1c and biomarkers of diabetes mellitus in Clinical Chemistry and Laboratory Medicine : ten years after.

Autor: Gillery P; Laboratory of Biochemistry-Pharmacology-Toxicology, Biology and Pathology Department, University Hospital of Reims, Reims, France.; Laboratory of Medical Biochemistry and Molecular Biology, UMR CNRS/ URCA n°7369, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France.
Jazyk: angličtina
Zdroj: Clinical chemistry and laboratory medicine [Clin Chem Lab Med] 2022 Oct 14; Vol. 61 (5), pp. 861-872. Date of Electronic Publication: 2022 Oct 14 (Print Publication: 2023).
DOI: 10.1515/cclm-2022-0894
Abstrakt: Since its discovery in the late 1960s, HbA 1c has proven to be a major biomarker of diabetes mellitus survey and diagnosis. Other biomarkers have also been described using classical laboratory methods or more innovative, non-invasive ones. All biomarkers of diabetes, including the historical glucose assay, have well-controlled strengths and limitations, determining their indications in clinical use. They all request high quality preanalytical and analytical methodologies, necessitating a strict evaluation of their performances by external quality control assessment trials. Specific requirements are needed for point-of-care testing technologies. This general overview, which describes how old and new tools of diabetes mellitus biological survey have evolved over the last decade, has been built through the prism of papers published in Clinical Chemistry and Laboratory Medicine during this period.
(© 2022 Walter de Gruyter GmbH, Berlin/Boston.)
Databáze: MEDLINE
Externí odkaz: